Rs 105/Share Dividend: Large Cap FMCG Stock Recommends Final Dividend, Scrip Jumps 6.47%

Procter & Gamble Hygiene and Health Care Ltd., a large-cap FMCG company, on Monday recommended a final dividend of Rs 105 per equity share. The company also announced its financial results for the fiscal quarter ended June 30, 2023.

"the Board of Directors of the Company at its meeting held today, inter alia, have recommended a final dividend of Rs. 105 per Equity Share (Nominal Value of Rs. 10/- each), for the Financial Year ended June 30, 2023. The divided shall be paid between November 24, 2023 to December 20, 2023, on approval of the Members at the 59th Annual General Meeting," the Board said in a filing to stock exchanges.

During the quarter, the Company delivered strong and balanced growth with sales of Rs 852 crore, up 10% versus year ago driven by strong brand fundamentals and integrated growth strategy. Profit After Tax (PAT) for the quarter was Rs 151 crore, versus Rs 43 crore year ago because of strong base business growth and one-time help, according to the regulatory filing by the company.

Further, for the fiscal ended June 30, 2023, the Company reported Profit After Tax (PAT) of Rs 678 crores, up 18% versus year ago including one-time tax impacts. Excluding these one-time tax impacts, Profit After Tax (PAT) is up 10% operationally.

Shares of P&G Hygiene and Health Care on Monday closed at Rs 16,495 per share, up 6.47% from the previous close. The stock hit intraday highs and lows of Rs 16,599 and Rs 15,444.80 on the BSE, respectively.

It has given 7.14% positive return in the last 1 week. In 6 months, it has given 19.85% return. In 1 year, it has given 18.04% return. In 3 and 5 years, it has given 64.48% positive return.

The stock's 52-week high is Rs 16,599 per share and 52-week low is Rs 13,101.05 per share. The market cap of the stock is Rs 53,543.98 Crore.

Disclaimer

The stock just highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.